Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casdatifan Monotherapy and Combination Therapies in ccRCC and Other Solid Tumors
NCT05536141Phase 1Recruiting
- Sponsor
- Arcus Biosciences
- Start
- Oct 2022
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of casdatifan in clear cell renal cell carcinoma (ccRCC) and solid tumor (15 cohorts), sponsored by Arcus Biosciences. Primary endpoints: Dose Limiting Toxicities at 4 months and Adverse Events at 4 months. Started Oct 2022; status: recruiting.
02
Drugs
casdatifan
03
Conditions
clear cell renal cell carcinoma (ccRCC)solid tumor
Beyond the preview
Go deeper on NCT05536141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05536141.